Study Of Induction Paclitaxel And Cisplatin Followed By Standard Radiotherapy Vs Hyperfractionated Radiotherapy And Cisplatin As Radiosensitizer For Patients With Unresectable Stage IIIA And IIIB Non Small Cell Lung Cancer

Abstract

This is a prospective randomized study of induction paclitaxel and cisplatin followed by standard radiotherapy (arm I, 17 patients) vs hyperfractionated radiotherapy and cisplatin as radiosensitizer (arm II, 16 patients) for patients with unresectable stage IliA and IliB NCSLC. The aim of this work is to determine response rate, duration of response, survival, and eva l uation of pattern of local and distant failure and assessment of the treatment toxicity. Regarding the response and survival, the overall response rate in arm I was 47% (all were PR no CR), 29.4 % MR, 11.7% SD and 1 1.7% PD. The median time to disease progression free was 8 months, the median survival duration was 11 months and the over all survival rate was 40%. rn arm II the over a ll re s ponse was 3 7.5% (all wer e PR no CR) 43% MR, 18.7% SD and no PD. The median time to disease progression free was

7.5 months, the median survival duration was 8 months and the over all survival rate was 36%. . Compared to arm I results no statistically significant difference was found in the response and overall survival rates among both groups, also the difference in disease-free survival was statistically insignificant.